Skip to main content
Clinical Trials/NCT05169125
NCT05169125
Unknown
Not Applicable

Effect of Reducing Dialysate Sodium Concentration on Blood Pressure Variability in Hemodialysis Patients: A Randomized Controlled Trial

Mansoura University0 sites80 target enrollmentJanuary 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hemodialysis Patients
Sponsor
Mansoura University
Enrollment
80
Primary Endpoint
blood pressure variability.
Last Updated
4 years ago

Overview

Brief Summary

In this study the investigators aim to test the effect of lowering dialysate sodium concentration on visit-to-visit blood pressure variability in hemodialysis patients who have achieved their dry weight.

Detailed Description

Cardiovascular diseases are considered the major cause of mortality in maintenance hemodialysis patients. Nevertheless, hypertension is recognized as an important modifiable risk factor for cardiovascular disease among hemodialysis (HD) patients. Apart from blood pressure levels, BP variability, which reflects the fluctuation in BP, has been described as an independent risk factor that linearly associated with all-cause and cardiovascular mortality in HD patients. BPV is categorized as either long or short term, based on the time interval over which it is considered. In the dialysis population, long-term BPV is typically defined on the basis of BP measurements taken at the start of each thrice-weekly hemodialysis treatment (interdialytic BPV). On the other hand, short-term BPV among dialysis patients can be considered in terms of variability that occurs during hemodialysis treatments (intradialytic BPV). Researchers believed that the mitigation strategies of BPV must be paid attention to. Sodium load is associated with thirst, fluid retention, interdialysis weight gain and hypertension for hemodialysis patients, therefore the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guideline highlighted the importance of limiting sodium intake and adequate sodium removal which is considered one of the most important goals of the dialysis therapy. Interestingly, a recent study showed that mild decrease in dialysate sodium concentration could improve systolic blood pressure variability in HD patients at their dry weight, thus improving blood pressure complications and subsequent complications. However, whether improving sodium balance could potentially contribute to better BPV management in HD patients has not been assessed in a randomized manner. Therefore, this study aims to investigate whether lowering dialysate sodium concentration could help mitigate long term (interdialytic) BPV in hemodialysis patients in a randomized controlled manner.

Registry
clinicaltrials.gov
Start Date
January 2022
End Date
July 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Hadeer Tarek Abdelaziz Gomaa

principal investigator

Mansoura University

Eligibility Criteria

Inclusion Criteria

  • Patients' age ≥18 years
  • Patients who had been on regular hemodialysis for at least 3 months.
  • Patients' residual daily urine output is less than 100 mL/day.
  • Pre study one week average systolic BP ≥120 mmHg but ≤ 180 mmHg.
  • Patients who have achieved their dry weight as assessed by clinical examination.
  • Predialytic serum sodium level ≥ 140mmol/l.
  • Kt/V ≥ 1.2

Exclusion Criteria

  • Patients who have advanced heart failure or permanent atrial fibrillation decompensated liver disease, neoplastic illness, overt edema.
  • History of acute cardiovascular accidents or infections during 3 months preceding entry into the study.
  • Patients prone to hypotension or other intradialytic adverse events.
  • Patients participating in another interventional study that may affect blood pressure.

Outcomes

Primary Outcomes

blood pressure variability.

Time Frame: 2 weeks after the study duration (3 months).

visit to visit blood pressure variability in both groups.

Secondary Outcomes

  • the frequency of intradialytic adverse events(2 weeks after the study duration (3 months).)
  • interdialytic weight gain(2 weeks after the study duration (3 months).)
  • antihypertensive medication regimen(2 weeks after the study duration (3 months).)

Similar Trials